Connection

ANITA DESWAL to Cardiotoxicity

This is a "connection" page, showing publications ANITA DESWAL has written about Cardiotoxicity.
Connection Strength

2.753
  1. Time to Personalize Surveillance for Cancer Therapy-Related Cardiac Dysfunction in HER2-Targeted Therapy: One Size Does Not Fit All. Curr Heart Fail Rep. 2026 Jul 22; 23(1).
    View in: PubMed
    Score: 0.959
  2. Early anthracycline cardiotoxicity in adolescents and young adults with sarcoma: a prospective echocardiographic study. ESC Heart Fail. 2026 May 05; 13(3).
    View in: PubMed
    Score: 0.236
  3. Standardizing the Clinical Approach to Cancer Therapy-Related Cardiac Dysfunction: Applying Cardio-Oncology Guidelines as a Practical Tool for Hematology and Oncology Providers. Cancer Med. 2026 Apr; 15(4):e71682.
    View in: PubMed
    Score: 0.235
  4. Radiation Doses to Cardiac Substructures Predict Elevation in High-sensitivity Cardiac Troponin T Levels in Radiation Therapy for Lung Cancer. Int J Radiat Oncol Biol Phys. 2026 Mar 15; 124(4):1124-1136.
    View in: PubMed
    Score: 0.228
  5. Cardiovascular toxicity of immune therapies for cancer. BMJ. 2024 05 15; 385:e075859.
    View in: PubMed
    Score: 0.206
  6. Myocardial Dysfunction in Patients with Cancer. Heart Fail Clin. 2022 Jul; 18(3):361-374.
    View in: PubMed
    Score: 0.181
  7. Cardiovascular Care of the Oncology Patient During COVID-19: An Expert Consensus Document From the ACC Cardio-Oncology and Imaging Councils. J Natl Cancer Inst. 2021 05 04; 113(5):513-522.
    View in: PubMed
    Score: 0.167
  8. Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment. J Am Heart Assoc. 2020 01 21; 9(2):e013757.
    View in: PubMed
    Score: 0.153
  9. Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association. J Clin Oncol. 2026 Aug; 44(22):2140-2155.
    View in: PubMed
    Score: 0.060
  10. Heart failure with preserved ejection fraction in cancer patients and survivors. A scientific statement of the Heart Failure Association of the ESC and the ESC Council of Cardio-Oncology. Eur J Heart Fail. 2025 Nov; 27(11):2152-2167.
    View in: PubMed
    Score: 0.057
  11. Cardio-Oncology and Heart Failure: a Scientific Statement From the Heart Failure Society of America. J Card Fail. 2025 02; 31(2):415-455.
    View in: PubMed
    Score: 0.053
  12. Circulating microRNAs and Cytokines as Prognostic Biomarkers for Doxorubicin-Induced Cardiac Injury and for Evaluating the Effectiveness of an Exercise Intervention. Clin Cancer Res. 2023 11 01; 29(21):4430-4440.
    View in: PubMed
    Score: 0.050
  13. Radiation-Induced Cardiovascular Disease: Mechanisms, Prevention, and Treatment. Curr Oncol Rep. 2022 05; 24(5):543-553.
    View in: PubMed
    Score: 0.044
  14. Cardiovascular safety profile of taxanes and vinca alkaloids: 30 years FDA registry experience. Open Heart. 2021 12; 8(2).
    View in: PubMed
    Score: 0.043
  15. Cardiovascular Toxicities of Androgen Deprivation Therapy. Curr Treat Options Oncol. 2021 04 17; 22(6):47.
    View in: PubMed
    Score: 0.042
  16. Modern Radiotherapy and Risk of Cardiotoxicity. Chemotherapy. 2020; 65(3-4):65-76.
    View in: PubMed
    Score: 0.040
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.